首页> 外国专利> Compound amino acid carboxilixo - 2 - 3 - 4 - ilo alcoxiisoxazol replaced that understands, Pharmaceutical Composition and Use thereof.

Compound amino acid carboxilixo - 2 - 3 - 4 - ilo alcoxiisoxazol replaced that understands, Pharmaceutical Composition and Use thereof.

机译:理解的复方氨基酸羧苄索-2--3-4-伊洛昔康唑,药物组合物及其用途。

摘要

1. 2-amine carboxylic acid derivatives substituted by (3-alcoxiisoxazol-4-il o) or sulfur analogues with general formula I or II, wherein R1 is optional alternative hydrogen, tar, acyl chloride, asphalt, cyclododecane (EN) ILO, ciloal-a LQ (EN / in) il Alq (EN / in) ILO or fenil Alq (EN / in); A is a hydrogen fuel coupling or spacing group; B is a CRA (nrrc) - cour5 group, wherein ra-rc is an independent hydrogen or tar, R5 is an opiva oximetry; or B is a third preparation group, wherein R2, R3 and R4 are independently selected from polyhydrogen and non aromatic hydrocarbons.Phenyl and goblin pitch are linked to a group of isomerized substances, or R3 and R4, to form pitch, acrylonitrile or pitch, or R4 and R2 are related to each other to form an optional group of sulphurous acid or pitch, or ch2-o-ch2; E is cour6, where R6 is defined as R5, or E is R5. Tetracarboxylic acid or tricarboxylic acid; X is o or s; E is o or s; they are excitatory amino acids (EAA),In particular, amperometric and / or NMDA receptor ligation is a tool for the treatment of cerebral ischemia, dehuntington's disease, aseptic epilepsy, Parkinson's disease, Alzheimer's disease, schizophrenia, pain, depression and anxiety. It also provides a pharmaceutical ingredient that includes them and uses it to make a pharmaceutical synthesis.
机译:1.被(3-alcoxiisoxazol-4-il o)或具有通式I或II的硫类似物取代的2-胺羧酸衍生物,其中R1是氢,焦油,酰氯,沥青,环十二烷(EN)ILO的可选替代基, ciloal-a LQ(EN / in)il Alq(EN / in)国际劳工组织或fenil Alq(EN / in); A是氢燃料偶合或间隔基团; B是CRA(nrrc)-cour5基团,其中ra-rc是独立的氢或焦油,R5是眼压测定法;或B是第三制备基团,其中R 2,R 3和R 4独立地选自多氢和非芳族烃。苯基和地精沥青与一组异构化物质或R 3和R 4连接形成沥青,丙烯腈或沥青,或R 4和R 2相互关联以形成任选的亚硫酸基团或沥青,或ch 2 -o-ch 2; E为cour6,其中R6定义为R5,或E为R5。四羧酸或三羧酸; X是o或s; E是o或s;它们是兴奋性氨基酸(EAA),尤其是安培和/或NMDA受体连接是治疗脑缺血,德亨丁顿氏病,无菌性癫痫,帕金森氏病,阿尔茨海默氏病,精神分裂症,疼痛,抑郁和焦虑的工具。它还提供了包含它们的药物成分,并将其用于药物合成。

著录项

  • 公开/公告号AR008880A1

    专利类型

  • 公开/公告日2000-02-23

    原文格式PDF

  • 申请/专利权人 H. LUNDBECK A/S;

    申请/专利号AR1997P104586

  • 发明设计人

    申请日1997-10-03

  • 分类号C07D261/12;C07D261/18;C07D413/04;C07D275/03;C07D417/04;A61K31/42;A61K31/41;A61K31/425;

  • 国家 AR

  • 入库时间 2022-08-22 01:57:35

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号